ImmunoHorizons
@immunohorizons.bsky.social
ImmunoHorizons is the #OpenAccess, fully peer-reviewed journal of The American Association of Immunologists, Inc. @immunologyaai.bsky.social
Editor-in-Chief: Bonnie N. Dittel, Ph.D.
Editor-in-Chief: Bonnie N. Dittel, Ph.D.
Researchers found that exogenous type I interferons, a major downstream product of STING activation, also upregulate CCL22 in cancer cells via a STING-dependent mechanism and that exogenous IFN-β can directly activate STING. Learn more in ImmunoHorizons: ow.ly/C11i50Xmw7h
November 4, 2025 at 3:31 PM
Researchers found that exogenous type I interferons, a major downstream product of STING activation, also upregulate CCL22 in cancer cells via a STING-dependent mechanism and that exogenous IFN-β can directly activate STING. Learn more in ImmunoHorizons: ow.ly/C11i50Xmw7h
Enhance your knowledge with the 2025 AAI Intro Course. Join expert faculty, such as Sarah Gaffen @slg1717.bsky.social, a past Deputy Editor of The JI, for a comprehensive overview of the basics of #immunology. Register now to build your repertoire with AAI from July 8-13 in LA! ow.ly/Uf7F50W2TU5
June 2, 2025 at 7:46 PM
Enhance your knowledge with the 2025 AAI Intro Course. Join expert faculty, such as Sarah Gaffen @slg1717.bsky.social, a past Deputy Editor of The JI, for a comprehensive overview of the basics of #immunology. Register now to build your repertoire with AAI from July 8-13 in LA! ow.ly/Uf7F50W2TU5
ImmunoHorizons (IH) is a fully #OpenAccess, peer-reviewed journal committed to advancing the knowledge of immunology and immunology education. Learn more about why you should publish in ImmunoHorizons today: ow.ly/BgxV50VEMTY.
April 25, 2025 at 7:32 PM
ImmunoHorizons (IH) is a fully #OpenAccess, peer-reviewed journal committed to advancing the knowledge of immunology and immunology education. Learn more about why you should publish in ImmunoHorizons today: ow.ly/BgxV50VEMTY.
ImmunoHorizons invites you to submit a manuscript for a special series on #autoimmunity that will showcase cutting-edge research and advances, offering an opportunity to share impactful findings. Learn more and submit today: ow.ly/WM4c50VEMJ6.
April 23, 2025 at 4:23 PM
ImmunoHorizons invites you to submit a manuscript for a special series on #autoimmunity that will showcase cutting-edge research and advances, offering an opportunity to share impactful findings. Learn more and submit today: ow.ly/WM4c50VEMJ6.
New clinical data evaluated MK-6194, an interleukin-2 mutein that selectively activates Tregs, for safety, pharmacokinetics, immunogenicity, and pharmacodynamics. The findings support MK-6194 as a potential treatment for #autoimmune disorders. Read now: ow.ly/XX8350VvOUb.
#WorldHealthDay
#WorldHealthDay
April 7, 2025 at 2:59 PM
New clinical data evaluated MK-6194, an interleukin-2 mutein that selectively activates Tregs, for safety, pharmacokinetics, immunogenicity, and pharmacodynamics. The findings support MK-6194 as a potential treatment for #autoimmune disorders. Read now: ow.ly/XX8350VvOUb.
#WorldHealthDay
#WorldHealthDay
New in ImmunoHorizons! Spinal cord injury induces infection and inflammation of rectal tissues containing gut-associated lymphoid tissue, leading to gut dysbiosis, neurogenic bowel dysfunction, and systemic diseases. See more: ow.ly/6Uuz50VrCQu.
April 4, 2025 at 1:46 PM
New in ImmunoHorizons! Spinal cord injury induces infection and inflammation of rectal tissues containing gut-associated lymphoid tissue, leading to gut dysbiosis, neurogenic bowel dysfunction, and systemic diseases. See more: ow.ly/6Uuz50VrCQu.
March 6, 2025 at 4:27 PM
ImmunoHorizons invites manuscript submissions for a Special Series on #autoimmunity. For more information, visit academic.oup.com/immunohorizo...
February 26, 2025 at 4:59 PM
ImmunoHorizons invites manuscript submissions for a Special Series on #autoimmunity. For more information, visit academic.oup.com/immunohorizo...